Samyapts personal page - To The Moon

Samyapts

Samyapts

No personal profile

5Follow

0Followers

0Topic

0Badge

2021-06-23

Good

Lynn Miller, Former Deputy General Counsel At Tesla, Joins Executive Team Of Autonomous Trucking Technology Company Plus

2021-06-22

Great!

EMA Says CHMP Approves 2 Additional Manufacturing Sites For Biontech/Pfizer's COVID-19 Vaccine

2021-02-27

That’s good to know

Pfizer COVID-19 vaccine reduces transmission after one dose -UK study

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3577510914607862,"uuid":"3577510914607862","gmtCreate":1614416890838,"gmtModify":1648691445529,"name":"Samyapts","pinyin":"samyapts","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/7cc7577f55a50e5a549d33ae99805e5d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":5,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.09","exceedPercentage":"80.20%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.22","exceedPercentage":"93.95%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.26","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.09","exceedPercentage":"80.43%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},"individualDisplayBadges":null,"crmLevel":7,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":123074553,"gmtCreate":1624405340572,"gmtModify":1703835513586,"author":{"id":"3577510914607862","authorId":"3577510914607862","authorIdStr":"3577510914607862","name":"Samyapts","avatar":"https://community-static.tradeup.com/news/7cc7577f55a50e5a549d33ae99805e5d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577510914607862"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123074553","repostId":"2145657710","repostType":2,"repost":{"id":"2145657710","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1624390489,"share":"https://ttm.financial/m/news/2145657710?lang=&edition=fundamental","pubTime":"2021-06-23 03:34","market":"hk","language":"en","title":"Lynn Miller, Former Deputy General Counsel At Tesla, Joins Executive Team Of Autonomous Trucking Technology Company Plus","url":"https://stock-news.laohu8.com/highlight/detail?id=2145657710","media":"Reuters","summary":"June 22 (Reuters) - :Lynn Miller, Former Deputy General Counsel At Tesla, Joins Executive Team Of Au","content":"<html><body><p>June 22 (Reuters) - :Lynn Miller, Former Deputy General Counsel At Tesla, Joins Executive Team Of Autonomous Trucking Technology Company Plus. ((Reuters.Briefs@Thomsonreuters.Com;)).</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lynn Miller, Former Deputy General Counsel At Tesla, Joins Executive Team Of Autonomous Trucking Technology Company Plus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLynn Miller, Former Deputy General Counsel At Tesla, Joins Executive Team Of Autonomous Trucking Technology Company Plus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-23 03:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>June 22 (Reuters) - :Lynn Miller, Former Deputy General Counsel At Tesla, Joins Executive Team Of Autonomous Trucking Technology Company Plus. ((Reuters.Briefs@Thomsonreuters.Com;)).</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BGC":"BGC GROUP","TISI":"Team Inc","TSLA":"特斯拉"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145657710","content_text":"June 22 (Reuters) - :Lynn Miller, Former Deputy General Counsel At Tesla, Joins Executive Team Of Autonomous Trucking Technology Company Plus. ((Reuters.Briefs@Thomsonreuters.Com;)).","news_type":1},"isVote":1,"tweetType":1,"viewCount":105,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129245152,"gmtCreate":1624375363676,"gmtModify":1703834942930,"author":{"id":"3577510914607862","authorId":"3577510914607862","authorIdStr":"3577510914607862","name":"Samyapts","avatar":"https://community-static.tradeup.com/news/7cc7577f55a50e5a549d33ae99805e5d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577510914607862"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129245152","repostId":"2145052264","repostType":2,"repost":{"id":"2145052264","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1624364681,"share":"https://ttm.financial/m/news/2145052264?lang=&edition=fundamental","pubTime":"2021-06-22 20:24","market":"hk","language":"en","title":"EMA Says CHMP Approves 2 Additional Manufacturing Sites For Biontech/Pfizer's COVID-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2145052264","media":"Reuters","summary":"European Medicines Agency:Ema : Two Additional Manufacturing Sites For Biontech/Pfizer’S Covid-19 Va","content":"<html><body><p>European Medicines Agency:Ema : <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> Additional Manufacturing Sites For Biontech/Pfizer’S Covid-19 Vaccine :22/06/2021.Ema - One Site, Located In Reinbek, Germany, Operated By Allergopharma Gmbh &amp; Co. Kg. The Other In Stein, Switzerland, Is Operated By Novartis Pharma.Ema Says  One Site, Located In Reinbek, Germany, Is Operated By Allergopharma Gmbh &amp; Co. Kg..Ema Says The <a href=\"https://laohu8.com/S/TWOA\">Two</a> New Sites Are Expected To Support The Continued Supply Of Comirnaty In The European Union..Ema Says This Recommendation Does Not Require A European Commission Decision And The Sites Can Become Operational Immediately.Further Company Coverage: Pfe.N. ((Reuters.Briefs@Thomsonreuters.Com ;;)).</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EMA Says CHMP Approves 2 Additional Manufacturing Sites For Biontech/Pfizer's COVID-19 Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEMA Says CHMP Approves 2 Additional Manufacturing Sites For Biontech/Pfizer's COVID-19 Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-22 20:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>European Medicines Agency:Ema : <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> Additional Manufacturing Sites For Biontech/Pfizer’S Covid-19 Vaccine :22/06/2021.Ema - One Site, Located In Reinbek, Germany, Operated By Allergopharma Gmbh &amp; Co. Kg. The Other In Stein, Switzerland, Is Operated By Novartis Pharma.Ema Says  One Site, Located In Reinbek, Germany, Is Operated By Allergopharma Gmbh &amp; Co. Kg..Ema Says The <a href=\"https://laohu8.com/S/TWOA\">Two</a> New Sites Are Expected To Support The Continued Supply Of Comirnaty In The European Union..Ema Says This Recommendation Does Not Require A European Commission Decision And The Sites Can Become Operational Immediately.Further Company Coverage: Pfe.N. ((Reuters.Briefs@Thomsonreuters.Com ;;)).</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145052264","content_text":"European Medicines Agency:Ema : Two Additional Manufacturing Sites For Biontech/Pfizer’S Covid-19 Vaccine :22/06/2021.Ema - One Site, Located In Reinbek, Germany, Operated By Allergopharma Gmbh & Co. Kg. The Other In Stein, Switzerland, Is Operated By Novartis Pharma.Ema Says  One Site, Located In Reinbek, Germany, Is Operated By Allergopharma Gmbh & Co. Kg..Ema Says The Two New Sites Are Expected To Support The Continued Supply Of Comirnaty In The European Union..Ema Says This Recommendation Does Not Require A European Commission Decision And The Sites Can Become Operational Immediately.Further Company Coverage: Pfe.N. ((Reuters.Briefs@Thomsonreuters.Com ;;)).","news_type":1},"isVote":1,"tweetType":1,"viewCount":309,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":366148849,"gmtCreate":1614419363781,"gmtModify":1704771707174,"author":{"id":"3577510914607862","authorId":"3577510914607862","authorIdStr":"3577510914607862","name":"Samyapts","avatar":"https://community-static.tradeup.com/news/7cc7577f55a50e5a549d33ae99805e5d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577510914607862"},"themes":[],"htmlText":"That’s good to know","listText":"That’s good to know","text":"That’s good to know","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/366148849","repostId":"2114371822","repostType":4,"repost":{"id":"2114371822","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1614335051,"share":"https://ttm.financial/m/news/2114371822?lang=&edition=fundamental","pubTime":"2021-02-26 18:24","market":"us","language":"en","title":"Pfizer COVID-19 vaccine reduces transmission after one dose -UK study","url":"https://stock-news.laohu8.com/highlight/detail?id=2114371822","media":"Reuters","summary":"LONDON, Feb 26  - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare ","content":"<p>LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.</p>\n<p>Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.</p>\n<p>“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.</p>\n<p>After separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.</p>\n<p>This compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.</p>\n<p>The study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.</p>\n<p>This suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.</p>\n<p>The level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.</p>\n<p>Britain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.</p>\n<p>“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”</p>\n<p>Key real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer COVID-19 vaccine reduces transmission after one dose -UK study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer COVID-19 vaccine reduces transmission after one dose -UK study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-26 18:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.</p>\n<p>Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.</p>\n<p>“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.</p>\n<p>After separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.</p>\n<p>This compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.</p>\n<p>The study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.</p>\n<p>This suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.</p>\n<p>The level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.</p>\n<p>Britain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.</p>\n<p>“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”</p>\n<p>Key real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2114371822","content_text":"LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.\nResearchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.\n“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.\nAfter separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.\nThis compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.\nThe study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.\nThis suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.\nThe level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.\nBritain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.\n“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”\nKey real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.","news_type":1},"isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":123074553,"gmtCreate":1624405340572,"gmtModify":1703835513586,"author":{"id":"3577510914607862","authorId":"3577510914607862","authorIdStr":"3577510914607862","name":"Samyapts","avatar":"https://community-static.tradeup.com/news/7cc7577f55a50e5a549d33ae99805e5d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577510914607862"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123074553","repostId":"2145657710","repostType":2,"repost":{"id":"2145657710","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1624390489,"share":"https://ttm.financial/m/news/2145657710?lang=&edition=fundamental","pubTime":"2021-06-23 03:34","market":"hk","language":"en","title":"Lynn Miller, Former Deputy General Counsel At Tesla, Joins Executive Team Of Autonomous Trucking Technology Company Plus","url":"https://stock-news.laohu8.com/highlight/detail?id=2145657710","media":"Reuters","summary":"June 22 (Reuters) - :Lynn Miller, Former Deputy General Counsel At Tesla, Joins Executive Team Of Au","content":"<html><body><p>June 22 (Reuters) - :Lynn Miller, Former Deputy General Counsel At Tesla, Joins Executive Team Of Autonomous Trucking Technology Company Plus. ((Reuters.Briefs@Thomsonreuters.Com;)).</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lynn Miller, Former Deputy General Counsel At Tesla, Joins Executive Team Of Autonomous Trucking Technology Company Plus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLynn Miller, Former Deputy General Counsel At Tesla, Joins Executive Team Of Autonomous Trucking Technology Company Plus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-23 03:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>June 22 (Reuters) - :Lynn Miller, Former Deputy General Counsel At Tesla, Joins Executive Team Of Autonomous Trucking Technology Company Plus. ((Reuters.Briefs@Thomsonreuters.Com;)).</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BGC":"BGC GROUP","TISI":"Team Inc","TSLA":"特斯拉"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145657710","content_text":"June 22 (Reuters) - :Lynn Miller, Former Deputy General Counsel At Tesla, Joins Executive Team Of Autonomous Trucking Technology Company Plus. ((Reuters.Briefs@Thomsonreuters.Com;)).","news_type":1},"isVote":1,"tweetType":1,"viewCount":105,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129245152,"gmtCreate":1624375363676,"gmtModify":1703834942930,"author":{"id":"3577510914607862","authorId":"3577510914607862","authorIdStr":"3577510914607862","name":"Samyapts","avatar":"https://community-static.tradeup.com/news/7cc7577f55a50e5a549d33ae99805e5d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577510914607862"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129245152","repostId":"2145052264","repostType":2,"repost":{"id":"2145052264","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1624364681,"share":"https://ttm.financial/m/news/2145052264?lang=&edition=fundamental","pubTime":"2021-06-22 20:24","market":"hk","language":"en","title":"EMA Says CHMP Approves 2 Additional Manufacturing Sites For Biontech/Pfizer's COVID-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2145052264","media":"Reuters","summary":"European Medicines Agency:Ema : Two Additional Manufacturing Sites For Biontech/Pfizer’S Covid-19 Va","content":"<html><body><p>European Medicines Agency:Ema : <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> Additional Manufacturing Sites For Biontech/Pfizer’S Covid-19 Vaccine :22/06/2021.Ema - One Site, Located In Reinbek, Germany, Operated By Allergopharma Gmbh &amp; Co. Kg. The Other In Stein, Switzerland, Is Operated By Novartis Pharma.Ema Says  One Site, Located In Reinbek, Germany, Is Operated By Allergopharma Gmbh &amp; Co. Kg..Ema Says The <a href=\"https://laohu8.com/S/TWOA\">Two</a> New Sites Are Expected To Support The Continued Supply Of Comirnaty In The European Union..Ema Says This Recommendation Does Not Require A European Commission Decision And The Sites Can Become Operational Immediately.Further Company Coverage: Pfe.N. ((Reuters.Briefs@Thomsonreuters.Com ;;)).</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EMA Says CHMP Approves 2 Additional Manufacturing Sites For Biontech/Pfizer's COVID-19 Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEMA Says CHMP Approves 2 Additional Manufacturing Sites For Biontech/Pfizer's COVID-19 Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-22 20:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>European Medicines Agency:Ema : <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> Additional Manufacturing Sites For Biontech/Pfizer’S Covid-19 Vaccine :22/06/2021.Ema - One Site, Located In Reinbek, Germany, Operated By Allergopharma Gmbh &amp; Co. Kg. The Other In Stein, Switzerland, Is Operated By Novartis Pharma.Ema Says  One Site, Located In Reinbek, Germany, Is Operated By Allergopharma Gmbh &amp; Co. Kg..Ema Says The <a href=\"https://laohu8.com/S/TWOA\">Two</a> New Sites Are Expected To Support The Continued Supply Of Comirnaty In The European Union..Ema Says This Recommendation Does Not Require A European Commission Decision And The Sites Can Become Operational Immediately.Further Company Coverage: Pfe.N. ((Reuters.Briefs@Thomsonreuters.Com ;;)).</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145052264","content_text":"European Medicines Agency:Ema : Two Additional Manufacturing Sites For Biontech/Pfizer’S Covid-19 Vaccine :22/06/2021.Ema - One Site, Located In Reinbek, Germany, Operated By Allergopharma Gmbh & Co. Kg. The Other In Stein, Switzerland, Is Operated By Novartis Pharma.Ema Says  One Site, Located In Reinbek, Germany, Is Operated By Allergopharma Gmbh & Co. Kg..Ema Says The Two New Sites Are Expected To Support The Continued Supply Of Comirnaty In The European Union..Ema Says This Recommendation Does Not Require A European Commission Decision And The Sites Can Become Operational Immediately.Further Company Coverage: Pfe.N. ((Reuters.Briefs@Thomsonreuters.Com ;;)).","news_type":1},"isVote":1,"tweetType":1,"viewCount":309,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":366148849,"gmtCreate":1614419363781,"gmtModify":1704771707174,"author":{"id":"3577510914607862","authorId":"3577510914607862","authorIdStr":"3577510914607862","name":"Samyapts","avatar":"https://community-static.tradeup.com/news/7cc7577f55a50e5a549d33ae99805e5d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577510914607862"},"themes":[],"htmlText":"That’s good to know","listText":"That’s good to know","text":"That’s good to know","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/366148849","repostId":"2114371822","repostType":4,"repost":{"id":"2114371822","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1614335051,"share":"https://ttm.financial/m/news/2114371822?lang=&edition=fundamental","pubTime":"2021-02-26 18:24","market":"us","language":"en","title":"Pfizer COVID-19 vaccine reduces transmission after one dose -UK study","url":"https://stock-news.laohu8.com/highlight/detail?id=2114371822","media":"Reuters","summary":"LONDON, Feb 26  - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare ","content":"<p>LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.</p>\n<p>Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.</p>\n<p>“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.</p>\n<p>After separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.</p>\n<p>This compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.</p>\n<p>The study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.</p>\n<p>This suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.</p>\n<p>The level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.</p>\n<p>Britain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.</p>\n<p>“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”</p>\n<p>Key real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer COVID-19 vaccine reduces transmission after one dose -UK study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer COVID-19 vaccine reduces transmission after one dose -UK study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-26 18:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.</p>\n<p>Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.</p>\n<p>“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.</p>\n<p>After separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.</p>\n<p>This compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.</p>\n<p>The study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.</p>\n<p>This suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.</p>\n<p>The level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.</p>\n<p>Britain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.</p>\n<p>“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”</p>\n<p>Key real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2114371822","content_text":"LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.\nResearchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.\n“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.\nAfter separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.\nThis compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.\nThe study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.\nThis suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.\nThe level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.\nBritain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.\n“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”\nKey real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.","news_type":1},"isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}